1246 related articles for article (PubMed ID: 17356050)
1. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
2. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; Prontera O; Fanelli F; Ciampaglia W; Cognigni GE; Pagotto U; Pasquali R
J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like factor 3 -- a new hormone related to polycystic ovary syndrome?
Szydlarska D; Grzesiuk W; Trybuch A; Kondracka A; Kowalik I; Bar-Andziak E
Endokrynol Pol; 2012; 63(5):356-61. PubMed ID: 23115068
[TBL] [Abstract][Full Text] [Related]
4. Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern.
Pelusi C; Fanelli F; Pariali M; Zanotti L; Gambineri A; Pasquali R
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1575-82. PubMed ID: 23928669
[TBL] [Abstract][Full Text] [Related]
5. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
6. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
Seyam E; Hefzy E
Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
Adams JM; Taylor AE; Crowley WF; Hall JE
J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
[TBL] [Abstract][Full Text] [Related]
13. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization.
Foong SC; Abbott DH; Zschunke MA; Lesnick TG; Phy JL; Dumesic DA
J Clin Endocrinol Metab; 2006 Jun; 91(6):2327-33. PubMed ID: 16551732
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
[TBL] [Abstract][Full Text] [Related]
15. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
[TBL] [Abstract][Full Text] [Related]
16. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
18. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H
J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
[TBL] [Abstract][Full Text] [Related]
19. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
20. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
Liang X; Zhuang G; Fan Q
Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
